Introduction
============

The carotid body (CB) is a small polymodal peripheral chemoreceptor standing out for its basic role in case of hypoxia, hypercapnia, acidosis, low glucose; in these circumstances, it promotes an adequate respiratory and cardiovascular response as well as other less studied stimuli ([@B7]; [@B145]). Two cell types can be distinguished in the CB, the 'neuron-like' chemosensitive type I cells and the 'glial-like' supportive type II cells. Type I cells synthetize and release many different neurotransmitters and neuromodulators, such as dopamine, acetylcholine, serotonin, histamine, ATP, glutamate, GABA, and substance P. Neurotransmitters and neuromodulators released by type I cells in great measure exert their activity on the afferent endings of the carotid sinus nerve ([@B161]), conveying the stimulation through the glossopharyngeal nerve and petrosal ganglion. The main excitatory stimuli are considered acetylcholine and ATP, binding to the ionotropic nicotinic and P2X~2~/P2X~3~ receptors, respectively. However, autocrine/paracrine modulation of type I cells is also of particular importance and is mainly performed through a series of metabotropic G protein-coupled receptors (GPCRs), such as A~2A~, D~1/2~, H~1/2/3~, M~1/2~, 5-HT~2A,~ and others (for comprehensive reviews on neurotransmitters in the CB, see [@B95]; [@B11]; [@B139], [@B140]). Conversely, metabotropic GPCRs are also present in afferent nerve endings and type II cells, where they play a role in neuromodulation of signaling between type I cells and afferent fibers ([@B187]; [@B141]). Many authors have emphasized the absolute peculiarity of the CB, characterized by "a plethora of neurotransmitters and neuromodulators, as well as an even broader spectrum of their receptors" ([@B140]). Apart from the above sensory innervation, the CB also shows sensory innervation from jugular and nodose ganglia, post-ganglionic sympathetic nerve fibers from the superior cervical ganglion, and preganglionic parasympathetic and sympathetic fibers reaching ganglion cells in the CB. Efferent parasympathetic and sympathetic innervation of the CB plays a pivotal role in modulation of blood flow ([@B42]).

-1The CB also shows a high level of structural plasticity, undergoing structural and functional changes during development (e.g., [@B159],[@B160]; [@B42]), aging (e.g., [@B45]; [@B199]) and as a consequence of environmental stimuli, such as chronic continuous hypoxia, taking place during acclimation to high altitude (e.g., [@B191]). In response to chronic hypoxia, type II cells can act in a stem cell-like manner, differentiating into precursors of neural cells that originate mature glomus cells ([@B148]; [@B155]).

The GPCR family involves about 800 human receptors that are organized into five subfamilies, namely classes A (the largest group), B, C, frizzled, and adhesion ([@B59]; [@B87]). Considering the structure, GPCRs have a similar conformation showing a peculiar seven TM (7TM) α-helical region, an extracellular amino-terminal segment and an intracellular carboxy-terminal tail ([@B188]). While the domain that is localized in the extracellular portion allows the ligand(s) -- receptor interaction, the TM region is subject to a conformational change when the binding with a ligand occurs; this change is then transmitted to the intracellular region of the GPCR responsible for activating the signaling cascade ([@B176]; [@B180]).

According to evidences from *in vitro* and *in vivo* studies, GPCR monomers can recognize/decode signals ([@B15]; [@B192]; [@B110]; [@B122]; [@B87]); in particular, an intrinsic plasticity characterizes GPCR monomers signaling, in fact GPCR activation can determine the onset of different signal transduction patterns, like the G proteins and/or arrestin pathways ([@B204]; [@B87]). Furthermore, it is established that GPCRs can functionally interact by sharing signaling pathways or by mechanisms of transactivation (see [@B108]; [@B87]). In the 1980s, however, [@B2] provided evidence suggesting that GPCRs could also establish structural receptor--receptor interactions (RRIs; see [@B86], [@B87] for recent reviews), in which they can associate with themselves (homodimerization) or with other proteins of the same family (heterodimerization). This concept was later confirmed in transfected mammalian cell systems but also in many different native tissues (i.e., central nervous system; mammary gland; liver; cancer tissues) (see [@B55]; [@B86]). It is a fact that class C GPCRs form constitutive homomers or heteromers ([@B105]; [@B87]). An example is represented by the metabotropic receptor for gamma-aminobutyric acid b (GABA~B~), that, in the central nervous system, constitutes the major inhibitory neurotransmitter ([@B25]; [@B156]). The receptor for GABA~B~, which is formed by the subunits GABA~B1~ and GABA~B2~, represents the typical example of constitutive heterodimer ([@B122]). Only GABA~B1~ can bind GABA; however, GABA~B2~, even if alone is not functional, is required as GABA~B1~ as such is considered immature due to the presence of a carboxy-terminal ER retention motif ([@B70]; [@B101]). Hence, after co-expression, the heterodimerization is the prerequisite to permit the masking of the retention domain and the subsequent translation of the active protein to the plasma-membrane ([@B183]). The oligomerization process in class A GPCR is a broadly debated topic of interest (see [@B60]; [@B87]). However, according to the consistent results obtained through multiple approaches, the possibility of class A GPCR complexes is strongly supported ([@B22]; [@B87]). In this respect, studies highlighting the occurrence of a specific and dynamic monomer/oligomer equilibrium in class A homodimers and heterodimers are of particular interest ([@B109]; [@B147]; [@B104]; [@B49]). In fact, according to their half-lives (determined by the association and dissociation rates) class A GPCR dimers are demonstrated to be often transient ([@B88]). This may contribute in explaining the opposing views regarding the role of class A GPCR monomers versus oligomers ([@B87]).

The amount of data proving the existence of GPCR heteromers showed a huge increase similarly to both development and diffusion of biophysical techniques able to detect the spatial proximity of protein molecules ([@B86]). They involve resonance energy transfer methods including bioluminescence and fluorescence resonance energy transfer (BRET and FRET, respectively), fluorescence complementation, total internal fluorescence microscopy, fluorescence correlation spectroscopy, assays based on bivalent ligands and proximity ligation assays (PLAs).

The basic molecular mechanism leading to the formation of the receptor assemblies are allosteric interactions ([@B103]; [@B64]). As recently outlined by [@B29], the cooperativity that emerges in the action of orthosteric and allosteric ligands of the GPCR forming the complex provides the cell decoding apparatus with sophisticated dynamics in terms of recognition and signaling ([@B76]; [@B87]). It has been shown, for instance, that GPCR heterodimerization exerts effects by altering or fine-tuning ligand binding, signaling, as well as internalization of GPCR protomers ([@B24]; [@B171]; [@B78]; [@B87]). Angiotensin II receptor (AT~1~) -- bradykinin receptor (B~2~) heterodimer (detected in smooth muscle, omental vessel, and platelets) provides an example: angiotensin II triggers inositol triphosphate (IP3) accumulation in a manner that is much more potent and effective than in the cells showing the expression of AT~1~ alone; conversely, IP3 accumulation sustained by bradykinin is slightly weaker in cells expressing the AT~1~--B~2~ heterodimer with respect to the cells expressing only B~2~ ([@B171]).

Many evidences highlight that dimers may be formed by different mechanisms ([@B87]). Receptor complexes can arise in plasma membrane under the action of hydrophobic forces ([@B69]). Receptor assembly may also occur in the endoplasmic reticulum (ER) before trafficking to the plasma membrane. ER is responsible of the structural quality of the synthetized receptors. Thus, only correctly folded receptors are allowed to exit while degradation occur for unfolded or misfolded proteins ([@B183]). Finally, recent data showed that GPCRs can be safely transferred by microvesicles from a source to a target cell where they become capable of recognizing and decoding their signal ([@B85]).

Since GPCRs are implicated in several human diseases and represent major pharmacological targets, GPCR oligomerization process, determining variations in the processes of agonist recognition, signaling, and trafficking of participating receptors via allosteric mechanisms ([@B64]), is of potential great importance for physiology and pharmacology, and new therapeutic strategies considering GPCR attitude to underwent toward several levels of receptor organization are under study ([@B49]).

Therefore, in a scenario where GPCR proteins are demonstrated to be present as monomer, the assumption that they may multimerize represents an interesting aspect to investigate. The purpose of the present article is to highlight indirect evidence of this with regard to the CB. In this tissue, indeed, the presence of multimeric GPCRs has not yet been consistently investigated. Thus, the main focus of the paper will be on possible homo-/heterodimers or mosaic receptors (already confirmed in other cell types) that could be present in the CB (type I and II cells, carotid sinus nerve afferents), with possible functional implications. The 'working hypothesis' of this paper could represent an interesting field of investigation aiming to clarify some aspects of chemoreception, neuromodulation and plasticity in the CB.

Investigative Approaches to GPCR Complexes
==========================================

As briefly discussed before, the term RRI emphasizes the occurrence of an interaction needing a direct physical contact between the involved receptor proteins responsible for the formation of multimeric assemblies of receptors (dimers or high-order oligomers) at the cell membrane level, acting as integrative input units of membrane-associated molecular circuits ([@B87]). Considerable efforts are currently being directed toward the identification of the most adequate strategy to discover such a supramolecular organization of GPCRs, but no single method is free from limitations giving rise to some discrepancy between various studies ([@B126]; [@B112]). Thus, evidence obtained through multiple approaches with consistent results is needed to identify receptor complexes ([@B22]).

In particular, an operational definition of RRI ([@B67]) can be exploited to devise experimental procedures fulfilling the following two measurable conditions:

1\. The binding of a ligand to one receptor determines a detectable change in the biochemical features of another receptor, that includes ligand recognition, decoding, and trafficking processes;

2\. Involved protomers have not only to be colocalized, but also in close proximity to each other (less than 10 nm), as indicated by specific techniques.

To explore the second point, biophysical and biochemical methods are presently available (see [@B100] for a review).

Biophysical Strategies
----------------------

Biophysical methods may be divided into three macro-groups that are fluorescence/luminescence-based techniques, specialized microscopic techniques and X-ray crystallography.

As far as fluorescence/luminescence-based techniques are concerned, bioluminescence resonance energy transfer (BRET) and fluorescence resonance energy transfer (FRET) were among the earliest proximity-based assays of this type that were used in studying GPCR heteromerization ([@B51]). Both techniques exploit the transfer of energy from a donor to an acceptor in a non-radiative manner (as a result of dipole--dipole coupling). If the donor is a fluorescent molecule with emission characteristics suitable to excite the acceptor, when they are in close proximity (∼10 nm) the result will be light emission from the acceptor fluorophore enabling the visualization of the subcellular location of specific receptor complexes.

Protein-fragment complementation assays have also been used to analyze GPCR heteromerization in living cells ([@B71]). In this approach, cells are transfected with one GPCR fused to a fragment of fluorophore and another GPCR fused to a complementary fragment. Reconstitution of the active fluorophore would occur only if the two receptors were in close proximity. It is noteworthy that a combination of this technique with BRET or FRET can be devised to demonstrate the presence of GPCR trimers or tetramers ([@B71]). In this respect, a specialized microscopic technique, namely atomic force microscopy, has also been explored to demonstrate the existence of GPCR complexes ([@B3]).

However, all the mentioned techniques show limitations in answering questions concerning the dynamic nature of receptor complexes. Thus, more recently, the details of the spatial and temporal organization of GPCR complexes have been addressed by using specialized microscopic techniques allowing the direct observation of the state and behavior of individual proteins in living cells. They include total internal reflection fluorescence microscopy ([@B90]; [@B87]), fluorescence correlation spectroscopy ([@B31]; [@B87]) and photoactivated localization microscopy (PALM; [@B98]).

X-ray crystallography represents a further significant experimental approach in the field. During the last years, crystallization techniques have been object of interest ([@B84]), determining important consequences for the analysis of GPCR complexes as well as an increase of the number of experimentally assessed structures ([@B87]).

Biochemical Strategies
----------------------

Spatial and temporal co-expression of GPCRs in cells and tissues is a necessary condition for the formation of more complex systems. This aspect can be investigated following biochemical approaches. The abundance of a specific mRNA can be detected by Northern-blot analysis, *in situ* hybridization, RT-PCR or microarray analysis. Immunohistochemistry and co-localization analysis ([@B2]) can be performed to detect GPCR co-expression and co-localization at protein level. The practical limit of this technique regards the necessity for high-quality antibodies also due to low GPCRs expression levels.

To identify possible complex formation, it is mandatory for biochemical studies extracting GPCRs from the membrane by use of detergent, although shielding their native conformation in detergent is not a trivial task ([@B149]).

Radiation inactivation technique (or target size method) take advantage of gamma rays or high energy electrons to disrupt polypeptides in order to identify the molecular weight of singular components. It is based on the inverse relationship existing between the size of a macromolecule and its dose-dependent inactivation. Hence, the probability to destroy a molecule increases along with its mass: larger is a protein and lower is the energy required to destroy it ([@B167]). For what it concerns GPCRs, the main limitation of the method is that this variation may be related to interaction with other proteins instead of oligomerization.

To overcome this limitation, co-immunoprecipitation can be used ([@B179]). Interestingly, this method in combination with confocal microscopy and FRET was used to detect homooligomerization of the 5-HT~2C~ receptors as well as the 5-HT~4~ homodimerization in combination with BRET ([@B100]).

More recently, evidence of heteroreceptor complexes in native tissues has been provided by *in situ* PLA ([@B186]). This technique could be adequate to highlight evidences regarding the presence of GPCR heteromers in tissue, giving new insights about basic biological mechanisms, heteroreceptor levels as well as their location. Thus, it allows to study the localization and modulation of heteroreceptor complexes, as formalin fixed tissue is used.

Cross-linking experiments are a further promising approach. They involve the use of assays based on bivalent ligands (agonists, antagonists, heteromer-selective antibodies, cross-linking reagents) allowing a direct targeting of the receptor complex ([@B196]) in cells and tissues.

Homo- or Hetero-Dimers Between A~1~ and/or A~2A~ Receptors
==========================================================

Adenosine receptor A~1~ homodimers have been identified in brain cortex of pigs by radioligand binding experiments ([@B32]). The capability of A~1~ receptors to form homodimers has also been demonstrated in Chinese hamster ovary (CHO) cells transfected with human A~1~ receptors ([@B81]) and in transfected human embryonic kidney (HEK-293T) cells expressing similar levels of A~1~ receptor as the native tissue ([@B82]). In bovine cortex, the existence of homomers was also shown through PLA ([@B82]).

The effects of homodimerization on the receptor function can be inferred from ligand binding assays. A~1~ receptor activation inhibits adenylate cyclase and decreases cAMP concentration. Caffeine is a non-selective adenosine receptor antagonist. In case of low caffeine concentrations (when caffeine only binds to one protomer of the empty homodimer), it determines an increase of the agonist affinity for the other protomer in the A~1~ receptor homodimer; whereas, at high concentrations (when caffeine highly saturates both protomers of the homodimer) caffeine behaves like an A~1~ antagonist with a reduction of the agonist binding to the receptors. Thus, caffeine modulates A~1~ agonist-induced cAMP decrease in a biphasic manner. Interestingly, this is a particular behavior for a classical adenosine receptor antagonist like caffeine and is a pharmacological behavior explanation-lacking without taking into account receptor dimers as a minimal quaternary structure. Moreover, this pharmacological ability can also give explanations about the biphasic effects exerted at low and high concentration of caffeine on locomotor activity ([@B82]).

As it regards the CB, adenosine is a well-known neurotransmitter produced in response to acute hypoxia. It can be directly released from type I cells, through an equilibrative nucleoside transporter, or it can be indirectly produced through breakdown of released ATP by ecto-5′-nucleotidase ([@B37]). Adenosine may act pre- and post-synaptically in the modulation of type I and afferents function. It enhances the firing pattern in the carotid sinus afferents through A~2A~ receptors ([@B35],[@B36]; [@B154]). Some discrepancies between studies have been reported about A~1~ localization into the CB structures ([@B14]). [@B168] described the presence of A~1~ in rabbit type I cells, through functional studies on cell cultures. Conversely, in the rat, post-synaptic localization has mainly been suggested as A~1~ receptors are significantly expressed in the cytoplasm of nodous and petrosal ganglia ([@B11]; [@B73]) and immunostaining of whole CB did not permit to specifically localize immunoreaction in type I cells ([@B10]). Possible species-related differences have been suggested and further analyses also on human material would be necessary. However, to reassume, A~1~ homodimerization may be hypothesized in nerve fibers and probably in those species expressing A~1~ receptors in type I cells.

A~2A~ homodimerization has also been assessed in the plasma membrane of transfected HEK-293T cells by BRET, FRET, time-resolved BRET and immunoblotting and biotinylating experiments. Evidences highlight that more of 90% of A~2A~ receptors are present as homodimers. In intracellular areas, the presence of a certain amount of monomeric species has been highlighted, suggesting that that they assemble into dimers before reaching cell surface ([@B26]; [@B124]).

In particular, [@B26] demonstrated that A~2A~ homodimers are the functional species at the cell surface. Even though A~2A~ homodimerization is quite constitutive, it is further influenced by specific ligands: agonists (i.e., CGS 21680) and antagonists (i.e., SCH 58261; caffeine) increase and decrease it, respectively ([@B124]).

Various authors confirmed the presence of A~2A~ receptor in the rat type I cells through several different techniques (RT-PCR studies, *in situ* hybridization analysis and immunohistochemistry) (e.g., [@B72]; [@B106]). [@B14] also demonstrated by Western-blot analysis the tendency of A~2A~ receptor to form homodimer in the CB similarly to the superior cervical ganglion and nucleus tractus solitarius. This is one of the few specific references about receptor dimerization in the CB.

However, there are not studies addressing the issue of how agonist/antagonists may modulate dimerization of adenosine receptors in the nerve fibers and/or type I cells or, conversely, how dimerization may play a role in their pharmacological actions. It must also be considered that environmental conditions (hypoxia, etc.) may modulate receptor expression as well as types of dimerization, potentially modulating pharmacological effects.

Apart from the above homodimers, the ability of A~1~ receptors to heterodimerize with A~2A~ receptors was also demonstrated in transfected cells by [@B56]. Heterodimerization of these two protomers was assessed *in vitro* and *in vivo* by [@B33], who confirmed the A~1~/A~2A~ heterodimer formation in rat striatal glutamatergic nerve terminals by immunogold detection and co-immunoprecipitation. Recently it has been shown that at the presynaptic membrane of cortico-thalamic glutamatergic terminals A~1~ receptors co-localizes and interacts with A~2A~ receptors, forming functional receptor heterodimer in the striatum ([@B52]).

The eventual demonstration of A~1~/A~2A~ heterodimers in type I cells and/or nerve fibers would be of particular interest in terms of modulation of the glutamatergic transmission. In fact, heterodimerization between the adenosine receptors A~1~ and A~2A~, which are responsible for opposite signaling pathways (inhibitory and excitatory actions, respectively) ([@B181]), has been suggested to exert a function in fine-tuning modulation of striatal glutamatergic neurotransmission by adenosine. Since A~1~ receptor shows higher affinity for adenosine than A~2A~, but A~1~ agonist affinity decreases when A~2A~ is activated, the possibility exists that glutamate release may be inhibited or stimulated by a switch mechanism depending on low and high concentrations of adenosine, respectively ([@B33]; [@B47]).

Hetero-Dimers Between Adenosine (A~1~ and A~2A~) and Purinergic (P2Y~1~, P2Y~2~, P2Y~12~) Receptors
===================================================================================================

P2Y~1~ ([@B195]; [@B187]) and P2Y~12~ ([@B28]) receptors have been demonstrated in type I cells, where they inhibit the hypoxia-induced rise in intracellular Ca^2+^. Conversely, in type II cells, P2Y~2~ receptors have been demonstrated ([@B194]), which produces a rise in intracellular Ca^2+^.

Purinergic receptors have also been reported to form homodimers and hetero-dimers with other purinergic and adenosine receptors (e.g., [@B172]). As previously detailed, A~2A~ receptors are expressed in type I cells ([@B72]; [@B106]) and A1 receptors have been reported in the type I cells of some species (rabbit) ([@B168]), although not confirmed in others (rat) ([@B74], [@B73]). Thus, in type I cells, many RRIs can be hypothesized: P2Y~1~/P2Y~1~, P2Y~1~/P2Y~12~, P2Y~12~/P2Y~12~, P2Y~1~/A~1~, P2Y~1~/A~2A~, P2Y~12~/A~1~, P2Y~12~/A~2A~ (e.g., [@B198]; [@B137], [@B136]; [@B172]). Physical interactions between A~1~ and P2Y~1~ receptors, for instance, produce a conformational change in the A~1~ binding pocket with acquisition of P2Y~1~-like agonistic pharmacology, i.e., a P2Y~1~ agonist may bind to the A~1~ receptor and produce an inhibition of adenylate cyclase which is prevented by A~1~ antagonist ([@B68]). All the above RRIs would be particularly intriguing as they would represent other ways of reciprocal modulation between purinergic and adenosine neurotransmission both in type I and II cells.

Homo- and Hetero-Dimers Between Dopamine Receptors (D~1~ and D~2~)
==================================================================

According to co-immunoprecipitation data gathered from both rat brain and cells showing co-expression of the D~1~ and D~2~ receptors, occurs the idea they may constitute the same heteromeric protein complex; moreover, according to immunohistochemistry studies, these receptors are convincingly co-expressed and co-localized within neurons of human and rat brain ([@B115]). For instance, a significant neuronal subpopulation in rat nucleus accumbens co-expresses D~1~ and D~2~ receptors, which can form a D~1~/D~2~ receptor complex ([@B92]; [@B89]). [@B163] also provided evidences concerning their co-expression in human embryonic kidney cells. In parallel, [@B163] and [@B89] demonstrated the ability of D~1~ and D~2~ receptors to oligomerize *in vivo* in rodent and monkey striata, respectively, through *in situ* PLA, *in situ* FRET and co-immunoprecipitation.

D~1~ and D~2~ monomers are coupled to G~s~ and G~i~ proteins, respectively, and they are usually considered to exert opposite effects at the cellular level ([@B92]). Conversely, the heterodimer D~1~/D~2~ is coupled to G~q/11.~ In the nucleus accumbens, the activation of this heterodimer-specific pathway determines an increase of calcium/calmodulin-dependent protein kinase IIα in contrast with the effect produced by the activation of the Gs-D~1~ receptor ([@B163]).

Numerous studies documented the presence of D~1~ receptor in the CB of various animals through Northern blot analysis, RT-PCR and pharmacological studies, although the precise location has not been verified ([@B4]; [@B13], [@B12]; [@B174]). [@B4] suggested expression in blood vessels. [@B13] suggested that D~1~ receptor could be expressed in nerve terminals (sensitive and sympathetic). Conversely, D~1~ receptors were identified in hamster type I cells through immunohistochemistry ([@B175]). D~2~ has been demonstrated in type I cells and nerve fibers of the rat CB by double immunofluorescence ([@B189]) and its expression is higher than D~1~ ([@B13]). The contemporary presence of D~1~ and D~2~ in type I cells and nerve fibers would support the hypothesis of heterodimerization in these structures. Exogenous dopamine may also inhibit Ca^2+^ responses in type II cells, supporting the presence of corresponding receptors ([@B116]; [@B117]) and of possible dimerization.

[@B93] explored the consequences of chronic hypoxia on D~2~ receptor expression in the arterial chemoreflex pathway. As regards the CB, the authors observed that the regulation of D~2~-receptor mRNA expression is time-dependent. Briefly, an initial increase of D~2~ receptor mRNA levels was observed after 6 and 12 h, with a subsequent decrease (24, 48 h) and a final significant increase after 168 h of hypoxia. In a noteworthy and analog study, [@B12] considered the effects induced by hypoxia on the expression levels of both D~1~ and D~2~ receptor mRNAs. The authors highlighted that in 1-day-old rabbits hypoxia affects the expression of D~2~- or D~1~-receptors mRNA in a manner that is age-dependent. D~2~- and D~1~-receptors transcript levels increased and decreased after exposure to moderate (15% O~2~) and severe (8% O~2~) hypoxia, respectively. Conversely, D~2~- and D~1~-transcript levels decreased independently of hypoxia intensities in adult rabbits. Unlike D~1~ receptors, changes in D~2~ receptor mRNA levels were independent on exposure time. The D~2~ role in the CB has been suggested not to be key under normal conditions, but rather in situations of chronic hypoxia, where D~1~ and D~2~ receptors density tends to change as previously discussed ([@B12]).

The above changes in the expression of the different dopamine receptors after hypoxia suggest the possibility of consequent changes in the amount of D~1~/D~2~ heterodimers. It is intriguing the idea that D~1~/D~2~ heterodimer formation may be under the influence of environmental stimuli, mainly hypoxia but possibly others, in the CB.

Hetero-Dimers Between Adenosine (A~1~ and A~2A~) and Dopamine (D~1~ and D~2~) Receptors
=======================================================================================

The co-localization of A~1~ and D~2~ receptors has been showed by immunofluorescence in rat cerebral cortex neurons ([@B77]). Moreover, the presence of A~1~/D~1~ complexes was detected in mouse fibroblast Ltk-cells, transfected with human A~1~, D~1~, and D~2~. While the formation of A~1~/D~1~ heteromers was confirmed by coimmunoprecipitation, A~1~ did not seem to form heterodimers with D~2~. A~1~ and D~1~ receptors, separately, also tend to form homodimers; however, the preferred form of dimerization for these two receptors still needs to be elucidated ([@B1]). Additionally, A~1~/D~1~ dimerization was also confirmed by FRET in HEK-293T cells ([@B177]).

Due to the possible presence of both A~1~ and D~1~ receptors in type I cells, a role by A~1~/D~1~ dimerization may be also be supposed. In particular, A~1~/D~1~ dimerization could represent a way of integration between agonists and/or antagonists for the two different monomers. For instance, [@B77] suggested that A~1~/D~1~ heteromerization may have a role in the antagonistic modulation of D~1~ receptor in the brain, thus having an impact on desensitization mechanism of D~1~ and receptor trafficking.

A~2A~/D~2~ heterodimers have also been demonstrated both in transfected SH-SY5Y ([@B91]; [@B193]) and HEK-293T cells ([@B138]), by immunoprecipitation followed by Western-blotting (SH-SY5Y) and BRET (HEK-293T). In addition, A~2A~/D~2~ heterodimers were identified in neuronal primary cultures of rat striatum by PLA ([@B138]) and cAMP accumulation experiments ([@B91]). A~2A~/D~2~ heterodimers have also been demonstrated in the mammalian striatum, with particular reference to the striatal enkephalin-containing GABAergic neurons that project to the globus pallidus and comprise the so-called indirect pathway ([@B57]; [@B66]; [@B173]; [@B186]; [@B47]; [@B5]). Thus, A~2A~/D~2~ heterodimers play an important role in the modulation of GABAergic striato-pallidal neuronal function ([@B16]). In particular, antagonistic A~2A~-D~2~ RRIs occur in the heterodimer, as demonstrated in striatal membrane preparations after incubation with the A~2A~ agonist CGS21680, leading to a decrease of the affinity of the high affinity D~2~ agonist-binding site ([@B66]; [@B87]). Relationships between A~2A~ and D~2~ and adenosine/dopamine cross-talks have been proposed as possible new therapeutic approaches for Parkinson's disease, schizophrenia, and drug addiction ([@B27]; [@B86]).

As previously discussed, both A~2A~ and D~2~ are expressed in type I cells of the CB, supporting the hypothesis of A~2A~/D~2~ heterodimer formation also in these cells. The reciprocal influences of the two receptor monomers in the A~2A~/D~2~ complex would be particularly intriguing, as adenosine and dopamine are among the main excitatory and inhibitory neurotransmitters in the CB. Some authors have proposed a functional interaction between A~2B~ and D~2~ receptors. In particular, if adenosine levels would become too high, activation of the low affinity A~2B~ would lead to increased dopamine secretion from type I cells ([@B38]; [@B121]) and inhibition of sensory discharge through pre- and post-synaptic D~2~ receptors ([@B35],[@B36], [@B37]; [@B202]; [@B141]). RRI between A~2A~ and D~2~ could represent an opposite way of neuromodulation, increasing signaling efficiency in the presence of low adenosine levels, through allosteric receptor--receptor inhibition of D~2~ signaling.

In rat type I cells, [@B34], [@B36]) also proposed a A~2B~-D~2~ receptor interactions on the basis of *in vitro* pharmacological experiments, although they did not demonstrate if physical RRI occur but only demonstrated an interaction at the adenylyl cyclase level. In particular, they showed that D~2~ agonists decrease catecholamine release and inhibit cAMP production in the CB and that these effects are prevented by A~2B~ agonists; conversely, D~2~ antagonists increase the release of catecholamines, this phenomenon being also prevented by A~2B~ antagonists. A~2B~-D~2~ RRI, however, have not yet been demonstrated to date in any cell type.

Homo- and Hetero-Dimers Between Opioid Receptors (μOR and δOR)
==============================================================

μOR forms homodimers ([@B123]) with an elevated stability, as demonstrated in transfected HEK-293 cells by BRET and radioligand binding assays ([@B190]). μOR/μOR homodimerization occurs prior of transportation to the cell membrane. [@B170] also proved μOR homodimerization in rat NK cells through Western-blot analysis and immunoprecipitation as well as immunohistochemistry and immunofluorescence.

Also δOR homodimerization was confirmed by Western-blotting and co-immunoprecipitation in different transfected cellular systems, such as CHO cells and COS cells ([@B40]). Data obtained by cross-linking experiments in CHO cells indicated that homodimerization does not depend on the expression level of the receptor. Subsequently, the occurrence of homodimers was also assessed in HEK-293T cells by BRET ([@B97]) and in rat NK cells by Western-blot assays, immunoprecipitation, immunohistochemistry, and immunofluorescence ([@B170]).

δOR/μOR heterodimers have also been demonstrated ([@B75]; [@B79]; [@B170]). The heteroreceptor complexes exhibit distinct pharmacological properties from that of the monomers. Low non-signaling doses of δ- or μ-ligands potentiate the binding and signaling of the receptors and the affinity of endomorphin-1 and δ-selective agonists is increased in the heteroreceptor complex, when compared to monomers ([@B99]). These properties appeared linked to changes in the signaling pathways activated by the heteroreceptor complexes as compared to individual receptors ([@B80]). In NK cells, in which δOR and μOR proteins exist as homo- and heterodimers, differences in cell function were observed depending on the prevalent type of receptor dimerization ([@B170]).

As suggested by [@B40] the dimerization also plays an important role in the internalization of the δOR receptor which in its monomeric form may not be internalized. This could be related to the mechanism that takes place after long-term exposure to opioid ligands. Dimerization of δOR receptors seems to be agonist dependent.

As it regards the CB, both μOR and δOR are expressed in type I cells ([@B94]; [@B166]). The expression of both receptors in type I cells suggests the occurrence of homo- and hetero-dimerization, with possible pharmacological implications. Perivascular nerve fibers have also been reported to express δOR ([@B94]) although further studies will be necessary for detection of other opioid receptor types.

Hetero-Dimers Between Dopamine (D~1~) and Opioid (μOR) Receptors
================================================================

Co-immunoprecipitation, BRET and cross-antagonism assays demonstrated the existence of D~1~/μOR heterodimers in both transfected HEK-293 cells and ventral striatum ([@B182]). D~1~ receptor antagonist can antagonize μOR-mediated signaling and function in a dopamine-independent manner, mostly likely via allosteric interactions through the D~1~/μOR heteromer. D~1~ antagonist (SCH23390) prevented opiate-induced activation of G-protein, inhibition of adenylyl cyclase, phosphorylation of ERK 1/2 and expression of c-fos in transfected cells expressing both receptors and in striatal tissues from wild type, but not DR KO, mice. The ability of an antagonist to inhibit signals originated by stimulation of the partner receptor is a biochemical characteristic that has been described for receptor heterodimers (cross-antagonism) ([@B182]).

As discussed above, D~1~ receptor and μOR were both assessed in the CB, supporting the hypothesis of corresponding RRI. Moreover, changes in the dynamic monomer/oligomer equilibrium may be postulated on the basis of environmental stimuli, as D~1~ expression levels, for instance, decrease in hypoxia conditions and along with exposure time ([@B12]).

Hetero-Dimers Between Dopamine (D~1~ and D~2~) and Histamine (H~3~) Receptors
=============================================================================

[@B107] assessed the presence of histamine receptors (H~1~, H~2~, H~3~) in the CB through RT-PCR studies. In particular, H~3~ has been detected in rat type I cells by immunohistochemistry ([@B113]; [@B43]; [@B184]). H~3~ antagonism results in increased chemosensory activity ([@B43]) and H3 activation inhibits the intracellular Ca^2+^ signaling mediated by activation of muscarinic receptors in type I cells ([@B184]). On the basis of the above and following findings, histamine receptors could also be included in the series of GPCRs with potential oligomerization in the CB.

In fact, [@B54] demonstrated the D~1~--H~3~ receptor heteromerization in mammalian transfected cells (HEK-293) by BRET and binding assays as well as in the neuronal cell model SK-N-MC by radioligand experiments. The presence of this heteromer in the brain (striatum) was then also proved by [@B132].

An antagonist acting on one of the receptor units that constitute the D~1~--H~3~ receptor heteromer can cause changes in conformation of the other receptor unit, thus, blocking specific signals that originate in the heteromer. This mechanism could be responsible for unsuspected GPCR antagonists-related therapeutic potentials ([@B54]). D~1~/H~3~ receptor heteromers work as processors integrating dopamine- as well as histamine-related signals involved in controlling the function of striatal neurons of the direct striatal pathway ([@B132]).

A strong and selective heteromeric interaction between D~2~ and H~3~ was also assessed by radioligand binding experiments in striatal membrane preparations and in co-transfected HEK-293 cells by BRET ([@B53]). According to agonist/antagonist competition experiments, a significant decrease of D~2~ receptors affinity for the agonist was encountered after stimulation of H~3~ receptors with several H~3~ agonists ([@B53]).

Hetero-Dimers Between Dopamine (D~2~) and Serotonin (5-HT~2A~) Receptors
========================================================================

5-HT~2A~/D~2~ heteroreceptor complexes were demonstrated by PLA and immunofluorescence in co-transfected HEK-293T cells ([@B125]; [@B20]), as well as in discrete regions of the ventral and dorsal striatum and nucleus accumbens ([@B20]), medial prefrontal cortex as well as in the pars reticulate of the substantia nigra in rat ([@B125]).

The functional properties of this complex are not yet completely clear ([@B125]). However, ligands with high 5-HT~2A~/D~2~ selectivity and partial agonistic activity on D~2~ have been recently identified as new antipsychotic drugs which do not significantly induce extrapyramidal side effects ([@B131]).

Serotonin is released by type I cells and it acts in a autocrine/paracrine manner on 5-HT~2~ receptors which are localized in type I cells, as proved by immunofluorescence and pharmacological/functional studies in the rat CB ([@B201]; [@B96]; [@B119]; [@B197]). Possible expression of 5-HT~2A~ in carotid sinus nerve terminals has also been reported ([@B141]). Serotonin is also considered to be involved in long-term facilitation of CB sensory discharge due to chronic intermittent hypoxia ([@B152]; [@B162]). The presence of 5-HT~2A~ and D~2~ in type I cells suggests the possibility of heterodimer formation, with functional roles to be investigated. 5-HT~2A~ and D~2~ mediate excitatory and inhibitory effects on type I cells and the role of dimerization in the modulation of the two response types is particularly intriguing.

Hetero-Dimers Between Dopamine (D~2~) and Neurotensin (NTS~1~) Receptors
========================================================================

Among CB receptors possibly interacting with D~2~ receptor there is also the neurotensin receptor 1 (NTS~1~), which has been demonstrated by immunohistochemistry in rat and human type I cells ([@B157]). D~2~-NTS~1~ complexes have also been highlighted in living HEK293T cells by BRET technology ([@B18]). Through these RRI neurotensin reduces dopamine binding and function at D~2~ receptor, moving dopamine transmission toward D~1~ receptor, which is not antagonized by NTS~1~ ([@B19]).

Homo- and Hetero-Dimers Between Melatonin Receptors (MT~1~ and MT~2~)
=====================================================================

MT~2~ receptors have the ability to form homodimers, as first demonstrated in HEK-293T transfected cells through BRET approaches (including single-cell BRET experiments), as well as Western-blotting and co-immunoprecipitation assays ([@B8]). However, it has also been observed that MT~2~ receptors tend to preferentially form heterodimers with MT~1~, as proved by BRET techniques (BRET donor saturation assay) in the same cell model ([@B9]).

The homodimerization of MT~2~ receptors is not modulated by ligands as it can exist in a constitutive manner in living cells. However, the speculated role of MT~2~ dimers is that they are required for explicating biological functions of cells being considered functional signaling units. Modulation of the signaling and trafficking occurs similarly to the GABA~B~ receptors ([@B8]).

As regards the presence of MT receptors in the CB, an *in situ* hybridization study showed MT~2~ expression in the rat type I cells whereas there are not yet data about MT~1~ ([@B185]). Thus, to date, we can suppose MT~2~ homodimerization in type I cells although further analyses could be of interest for MT~1~ detection.

Galanin Receptor (Gal~1~, Gal~2~) Heteromers
============================================

Galanin ([@B129]) and galanin receptors 1 (Gal~1~) and 2 (Gal~2~), but not 3 (Gal~3~), ([@B158]) have been demonstrated by immunohistochemistry in rat type I cells. Galanin is known to regulate the differentiation of neural stem cells and plasticity responses in the nervous system (e.g., [@B39]) and it has been suggested that galanin expression in chemoreceptor cells could provide a signal for neurogenesis and chemoreceptor cell differentiation ([@B44]; [@B128]).

As it concerns this paper, galanin receptors are particularly intriguing because evidence is given about the possibility of Gal~1~-Gal~2~, D1-Gal~1~, Gal-NPY~*Y*1~, Gal~1~-Gal~2~-NPY~*Y*2~ or Gal~1~-Gal~2~-AT~1~ heteromers, which can be postulated in type I cells (reviewed in [@B65]).

Although there are not specific data about the expression of the different NPY receptor types in the CB, NPY immunoreactivity has been identified in nerve fibers as well as type I cells of dog, monkey and rat CB ([@B143], [@B144]). In the rat CB, a reduction in NPY-immunoreactive type I cells was observed from postnatal week 2 onward; conversely, NPY-immunoreactive fibers mainly increase since week 2 after birth ([@B144]).

The local renin-angiotensin system in the CB has been extensively studied in the past years (e.g., [@B63]; [@B61]; [@B111]) and angiotensin II receptor type 1 (AT~1~) has been identified in rat type I ([@B62]; [@B6]) and type II ([@B133]) cells. In the rat, AT~1~ receptors are also up-regulated in response to hypoxia ([@B63]).

Homo- and Hetero-Dimers Between Endothelin Receptors (ET*~A~* and ET*~B~*)
==========================================================================

Endothelin 1 (ET-1) receptors type A (ET*~A~*) and B (ET*~B~*) may form homo- and heterodimers, although the functional implications of different dimerization are still largely unknown. Their behavior was studied after expression in transfected HEK-293T cells by immunoprecipitation, immunoblotting and FRET ([@B48]). These results confirmed the previous data by [@B83] who adopted FRET too, co-localizing ET-1 receptors at the plasma membrane. Furthermore, the latter speculated that ET-1-receptors homodimerization (as well as homo-oligomerization) is constitutive and ligand-independent ([@B48]).

Type I cells synthetize and release ET-1, which may act in autocrine/paracrine manner on the same type I cells through both the above receptors. Chronic continuous hypoxia upregulates ET-1 and ET*~A~* receptor, suggesting a critical role in chronic hypoxia-induced increased chemosensitivity in the rat CB ([@B30]). Chronic intermittent hypoxia is also known to enhance the CB chemosensory and ventilatory responses to acute hypoxia and produce long-term sensory potentiation of chemosensory discharges (e.g., [@B153], [@B151]; [@B165]; [@B150]). Chronic intermittent hypoxia has been reported to determine an upregulation of ET-1 and ET*~B~* receptor, but not of ET*~A~* receptor, in adult cats ([@B164]); conversely, upregulation of ET-1 and ET*~A~* receptor, but not ET*~B~* receptor, have been reported in neonatal ([@B150]) and adult ([@B151]) rats.

Endothelin rise intracellular Ca^2+^ in cultured type II cells ([@B134]). Stimulation of ET*~B~* receptors by ET-1 has been reported to play a role in proliferation of stem cells derived from type II cells and CB hyperplasia following chronic hypoxia ([@B155]).

Thus, RRIs between ET-1 receptors can be hypothesized in type I and II cells. Hypoxia-induced changes in the expression of two different receptor types, together with the involvement of ET-1 in functional/structural modifications, suggests the idea that changes in the monomer/(homo/hetero)-dimer equilibrium may also play a role.

ET*~B~* receptor has also been reported to undergo physical interactions with AT~1~ receptor located in the cells of renal proximal tubule ([@B200]). RRI between the two receptors would be particularly intriguing in the CB, due to their roles in hypoxia responses.

Hetero-Dimers Between GABA (GABA~*B*2~) and Muscarinic (M~2~) Receptors
=======================================================================

[@B23] demonstrated by FRET that GABA~*B*2~ is co-localized and directly associates with M~2~ receptor in neuronal PC12 cells. In parallel, the authors observed that in another cell model, i.e., HEK-293T, GABA~B1~ is also required for GABA~*B*2~/M~2~ heterodimerization, contrary to what was observed in PC12. Moreover, through co-immunoprecipitation and immunostaining experiments, the authors supported that signaling complexes GABA~*B*2~/M~2~ exist also *in vivo* in the brain cortex. The association seems to be specific since GABA~*B*2~ did not associate closely with other related muscarinic receptors (M~1~) or with a different GPCR (μOR).

The findings that M~2~ and GABA~*B*2~ are co-localized and associate in cortical neurons, which overlap with brain regions that receive cholinergic projections, suggest that the heterodimer is involved in a novel mechanism for enhancing cholinergic signaling in the brain. In fact, expression of GABA~*B*2~ in M~2~-expressing neurons would allow some neurons to maintain muscarinic signaling during elevated or chronic agonist exposure ([@B23]).

Type I cells of the CB express both GABA~B1~ and GABA~*B*2~ subunits, as confirmed by RT-PCR studies. In addition to molecular biology evidences, localization of GABA~*B*2~ receptor subunits in sections of the CB was also assayed by immunofluorescence which assessed positive immunoreactivity for the receptor subunit in type I clusters ([@B50]). [@B178] demonstrated the expression of M~2~ mRNA and the presence of the receptor protein, by RT-PCR and immunohistochemistry, respectively. In particular, regarding localization, immunohistochemical analysis highlighted M~2~ presence in type I cells and petrosal afferent terminals. GABA and acetylcholine ([@B41]) show inhibitory and excitatory actions, respectively, on type I cells. The possible occurrence of dimerization may have a role in the reciprocal modulation of actions of the two neurotransmitters.

Muscarinic receptors are also present in type II cells, as muscarinic agonists elicit an increase of intracellular Ca^2+^ levels in these cells ([@B187]; [@B134]), but there are not data about the possible expression of GABA receptors too.

Cannabinoid Receptor (CB1) Heteromers
=====================================

The CB~1~ receptor was found to be expressed in the CB by techniques such as RT-PCR, immunohistochemistry and *in situ* hybridization, although its levels were relatively low ([@B130]). These findings suggest that endocannabinoids may have an impact on blood flow regulation in the CB, therefore affecting the oxygen pressure and respiratory control. However, the CB~1~ function in CB needs to be further investigated, as data present in another study on CB~1~ were somewhat discording ([@B169]).

The CB~1~ can form heterodimers with many other different GPCRs which are also assessed to be present in the CB; among these δOR, μOR, A~2A~ and D~2~ receptors. In particular, the ability of CB~1~ and D~2~ receptors to form heterodimers was demonstrated in co-transfected cells (HEK-293T) through co-immunoprecipitation and FRET techniques ([@B102]; [@B127]). It is noteworthy that the activation of CB~1~-D~2~ receptor heterodimer can have completely opposite effects than activation of the individual receptors.

The above receptors have also been demonstrated to oligomerize in receptor mosaics so that the presence of these complexes may also be postulated for the CB. In particular, the existence of a CB~1~-D~2~-A~2A~ receptor mosaic has been demonstrated, where CB~1~ receptor activation removes the D~2~ inhibition of the A~2A~ receptor signaling ([@B68]; [@B127]). The above receptor mosaicism could represent a further way of subtle reciprocal modulation between different neurotransmitters.

Heterocomplexes Between GPCR and Other Receptor Types
=====================================================

G protein-coupled receptors may undergo direct interactions with other membrane receptors, such as ion channel receptors or receptor tyrosine kinases ([@B21]). Some of these complexes can be postulated in the CB, with possible roles in modulation of neurotransmission and plasticity.

For instance, NMDA receptor subunits 1, 2A and 2B have been detected in CB, through RT-PCR, and type I cells, through immunohistochemistry. Chronic intermittent hypoxia also increases the expression of NMDA~1~ and NMDA~2B~ receptors ([@B120]). It is noteworthy that D~1~ receptors can regulate the function of the NMDA receptor by means of direct protein--protein interactions between the carboxyl terminals of D~1~ receptor and NMDA~1~ and NMDA~2A~ ([@B114]; [@B118]), stimulating NMDA receptor-mediated long-term potentiation ([@B135]).

FGF receptor 1, which is a tyrosine kinases receptor, has been reported to undergo direct RRI with A~2A~ receptor ([@B58]; [@B17]). In particular, as demonstrated in PC12 cells (showing a series of similar properties with type I cells), contemporary activation of the two receptors, but not the single ones, induces activation of the MAPK/ERK pathway, differentiation and neurite extension ([@B58]). The majority of human CB's type I cells have shown a weak to moderate cytoplasmic immunostaining for FGF~1~ receptor ([@B46]). In particular, FGF~1~ receptor immunoreactivity was shown in type I cells in postnatal rat CB cultures, in both normoxic and hypoxic conditions, as well as in bFGF presence or absence ([@B146]). bFGF increased both inward Na^+^ and outward K^+^ currents after 2 days of treatment on cultured type I cells from E18-19 rat pups ([@B203]). In cultures from rat E17-E19 CB, bFGF increases survival and BrdU incorporation; in postnatal P1-P3 cultures, bFGF still stimulates DNA synthesis but does not affect survival. In fetal rat glomus cells, bFGF stimulates neuronal differentiation, producing neurite outgrowth and inducing neurofilament immunoreactivity; these changes can no longer be detected in postnatal cultures ([@B142]). Given the concomitant expression of A~2A~ receptors in type I cells, an heterocomplex could be hypothesized. Moreover, the above developmental changes in the FGF action could partially derive by changes in the monomer--heteromer equilibrium. It is known, for instance, that the expression of A~2A~ receptors in the rat type I cells decreases by PN14 ([@B74]).

It is noteworthy that A~2A~-D~2~-FGF receptor mosaic has also been highlighted in other cell types ([@B67]) and could represent a further way of integration between neuromodulation and plasticity mechanisms.

Conclusion and Future Perspectives
==================================

The CB is characterized by the production and release of many different neurotransmitters and neuromodulators which act on various receptor types identifiable on type I and II cells and nerve fibers. Although the main receptors involved in conveying excitatory stimuli from type I cells to afferent nerve fibers are ionotropic (nicotinic, P2X~2~/P2X~3~), a wide series of GPCRs is also expressed in the various structures involved in chemoreception, exerting modulation of neurotransmission. In other transfected and native cell types, experimental evidence has been provided about the existence of RRIs between GPCRs, with production of homodimers, heterodimers or high-order complexes (receptor mosaics) which may modify ligand binding, signaling and internalization of the protomers. In the present paper, we have reviewed most literature data reporting the contemporary expression in type I cells, type II cells or afferents of GPCRs which are able to physically interact with each other to form homo/hetero-complexes. This is a prerequisite for postulating dimerization and/or oligomerization in the CB. RRIs are particularly intriguing to be hypothesized in the CB, where *in vitro*/*in vivo* pharmacological/functional data are available about cross-talks between different neurotransmitters/neuromodulators or 'paradoxical' response changes with different concentrations/doses. At least in some cases, such findings could be interpreted through the existence of direct RRIs. Nevertheless, few authors have considered the possibility of di/oligo-merization in the CB ([@B34], [@B36]) and to the best of our knowledge there are not studies addressing this aspect through up-to-date methodology (see corresponding paragraph). The literature data reviewed in the present paper support the possibility of RRI in the CB and stress the potential implications of di/oligomerization for chemoreception, neuromodulation and plasticity. It is known, in fact, that the expression of certain receptors varies in response to development or environmental stimuli (hypoxia, hyperoxia, etc.); changes in the dynamic monomer/oligomer equilibrium may be the consequence, with correlated functional implications.

In the present paper, we have collected indirect evidence of our 'working hypothesis,' identifying the most significant homo/hetero-complexes which would be worthwhile to be studied in the CB. The direct identification of homo/hetero-complexes in type I, type II and afferent terminations and the characterization of their functional role and relevance in the chemoreception could represent an exciting field of investigation. As previously stated, demonstration of RRIs in the CB should include (1) assessment of colocalization in "close proximity" of two or more receptors and (2) detectable biochemical/functional change in one receptor induced by the binding of a ligand to another receptor. We have here revised literature data highlighting colocalization of different receptors in the various elements of the CB (i.e., type I and II cells, nerve terminals). In addition, colocalization of other receptors could be preliminarily investigated through double immunofluorescence or *in situ* hybridization, both in CB tissue samples and cell cultures.

However, colocalization is just a necessary condition to have direct RRIs and the demonstration of close proximity (i.e., a distance lower than 10 nm) between receptor molecules must be provided. To date, many methods of both biochemical and biophysical nature are available to accomplish this task and most of them could be applied to CB cell cultures. In particular, BRET, FRET or atomic force microscopy could be considered the most useful approaches. Interestingly, *in vitro* models allow to detect changes in cultured CB cells as a response to external pharmacological or environmental (hypoxia, hyperoxia, etc.) stimuli; we have hypothesized that RRIs may increase or decrease in response to external actions. Dynamic modifications of RRIs could also be analyzed in living cells through experimental techniques such as total internal reflection fluorescence microscopy, fluorescence correlation spectroscopy and PALM. Apart from cell cultures, heterocomplexes could be identified in native formalin-fixed CBs through *in situ* PLA, an approach that would even permit the identification of eventual changes in RRIs with respect to experimental conditions of *in vivo* models.

Once demonstrated physical RRIs, functional approaches in cell cultures would have to verify how the agonist/antagonist to one receptor may modify the response of the other receptor(s) toward the corresponding agonists/antagonists.

In conclusion, many *in vitro* and *in vivo* models are available, for research in CB structure/function, which represent adequate material for the application of consistent methods of analysis of potential RRIs.
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